A prospective randomized trial on CellCept© (Mycophenolat Mofetil) in risk penetrating keratoplasty
Phase 4
- Conditions
- CellCept5-125: nullH44.5Degenerated conditions of globe
- Registration Number
- DRKS00000011
- Lead Sponsor
- Hoffmann-La Roche AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 98
Inclusion Criteria
Keratoplasty with increased risk for immunologic graft rejection in the abscence of other risk factors for graft failure. (repeat keratoplasty, steroid-response, limbo-keratoplasty, oversized graft.
Exclusion Criteria
Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method